Reactive protein, plasminogen activator inhibitor type-1 (PAI-1) levels, PAI-1 promoter 4G/5G polymorphism and acute myocardial infarction

Xuelei CAO; Changyong ZHOU; Lei YIN; Shaochun WANG; Xiuling JIA; Huan HUANG; Xiaohong SUN.
Journal of Geriatric Cardiology ; (12): 147-151, 2010.
Artículo en Zh | WPRIM | ID: wpr-473240

Documentos relacionados

  1. Relationship of Plasminogen Activator Inhibitor 1 4G/5G Gene Polymorphism and Nontraumatic Lunatum Avascular Necrosis.
  2. The Role of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Placenta-Mediated Pregnancy Complications: A Systematic Review.
  3. Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients.
  4. Quantile-specific heritability of plasminogen activator inhibitor type-1 (PAI-1, aka SERPINE1) and other hemostatic factors.
  5. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
  6. The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels.
  7. Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study.
  8. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.
  9. Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson's disease in Chinese patients.
  10. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.